Journal of Substance Abuse Treatment
Volume 28, Issue 3 , Pages 247-254 , April 2005

Influence of psychotherapy attendance on buprenorphine treatment outcome

  • Iván D. Montoya, M.D., M.P.H.

      Affiliations

    • Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Rockville, MD 20892, USA
    • Corresponding Author InformationCorresponding author. Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, 6001 Executive Blvd. Bethesda, MD 20892-9551, USA. Tel.: +1-301-443-8639; fax: +1-301-443-2599.
    • ,
  • Jennifer R. Schroeder, Ph.D.

      Affiliations

    • Clinical Pharmacology & Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA
    • ,
  • Kenzie L. Preston, Ph.D.

      Affiliations

    • Clinical Pharmacology & Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA
    • ,
  • Lino Covi, M.D.

      Affiliations

    • Clinical Pharmacology & Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA
    • ,
  • Annie Umbricht, M.D.

      Affiliations

    • Clinical Pharmacology & Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA
    • ,
  • Carlo Contoreggi, M.D.

      Affiliations

    • Brain Imaging Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA
    • ,
  • Paul J. Fudala, Ph.D.

      Affiliations

    • University of Pennsylvania School of Medicine and the Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    • ,
  • Rolley E. Johnson, Pharm.D.

      Affiliations

    • Reckitt Benckiser Pharmaceuticals, Inc. and Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD 21224, USA
    • ,
  • David A. Gorelick, M.D., Ph.D.

      Affiliations

    • Clinical Pharmacology & Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA

Received 22 August 2004 ,Revised 22 August 2004 ,Accepted 11 January 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0740-5472(05)00016-4

doi: 10.1016/j.jsat.2005.01.004

Journal of Substance Abuse Treatment
Volume 28, Issue 3 , Pages 247-254 , April 2005

Article Tools

* Image Usage & Resolution